Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1995-10-11
2001-09-04
Schwadron, Ronald B. (Department: 1816)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S002000, C435S007100, C435S007240, C435S007200, C435S007210, C435S325000, C435S372300, C435S189000, C436S503000, C436S501000, C436S813000, C424S093710
Reexamination Certificate
active
06284476
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to various therapeutic methodologies derived from the recognition that certain abnormal cells present complexes of human leukocyte antigens and peptides derived from tyrosinase on their surfaces. In addition, it relates to the ability to identify those individuals diagnosed with conditions characterized by cellular abnormalities whose abnormal cells present this complex, the presented peptides, and the ramifications thereof.
BACKGROUND AND PRIOR ART
The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T cell response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens (“HLA”), or major histocompatibility complexes (“MHCs”), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al.,
Advanced Immunology
(J. P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cell and complexes of HLA/peptide is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. This mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Recently, much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, Science 257: 880 (1992); Fremont et al., Science 257: 919 (1992); Matsumura et al., Science 257: 927 (1992); Latron et al., Science 257: 964 (1992).
The mechanism by which T cells recognize cellular abnormalities has also been implicated in cancer. For example, in PCT application PCT/US92/04354, filed May 22, 1992, published on Nov. 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs. The genes are said to code for “tumor rejection antigen precursors” or “TRAP” molecules, and the peptides derived therefrom are referred to as “tumor rejection antigens” or “TRAs”. See Traversari et al., Immunogenetics 35: 145 (1992); van der Bruggen et al., Science 254: 1643 (1991), for further information on this family of genes.
In U.S. patent application Ser. No. 07/938,334, now U.S. Pat. No. 5,405,940 the disclosure of which is incorporated by reference, nonapeptides are taught which bind to the HLA-A1 molecule. The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind one HLA molecule, but not others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.
The enzyme tyrosinase catalyzes the reaction converting tyrosine to dehydroxyphenylalanine or “DOPA” and appears to be expressed selectively in melanocytes (Muller et al., EMBOJ 7: 2715 (1988)). An early report of cDNA for the human enzyme is found in Kwon, U.S. Pat. No. 4,898,814. A later report by Bouchard et al., J. Exp. Med. 169: 2029 (1989) presents a slightly different sequence. A great deal of effort has gone into identifying inhibitors for this enzyme, as it has been implicated in pigmentation diseases. Some examples of this literature include Jinbow, WO9116302; Mishima et al., U.S. Pat. No. 5,077,059, and Nazzaropor, U.S. Pat. No. 4,818,768. The artisan will be familiar with other references which teach similar materials.
None of these references teach or suggest, however, that tyrosinase may be treated in a manner similar to a foreign antigen or a TRAP molecule—i.e., it has now been found that in certain cellular abnormalities, such as melanoma, tyrosinase is processed and a peptide derived therefrom forms a complex with HLA molecules on certain abnormal cells. These complexes are recognized by cytolytic T cells (“CTLs”), which then lyse the presenting cells. The ramifications of this surprising and unexpected phenomenon are the subject of the invention, which is described in greater detail in the disclosure which follows.
REFERENCES:
patent: 4898814 (1990-02-01), Kwon
patent: 9220356 (1992-11-01), None
Zemmour et al., HLA class I nucleotide sequences, 1992, Immunogenetics 37: 239-250 (1993).
Boon, Int. J. Cancer, 54: 177-180, 1993.*
Dermer, Bio/Technology, 12: 320, 1994.*
Hode, Chapter 20, from; Fundamentals of Immunology, Second Edition, Ed. W.E. Paul, Raven Press, 1990, pp. 606 and 618.*
Wolfel et al., Eur J. Immunol., 24(3), 759-64, 1994.*
Brichard et al., J. Exp. Med., 178, 489-495, 1993.*
Foon, Canc. Res., 49: 1621-39, 1989.*
Osband et al., Imm. Today, 11: 193-195, 1990.*
Kwon, et al., “Isolation and sequence of a cDNA clone for Human tyrosinase that maps at the mouse c-albino locus,” Proc. Natl. Acad. Sci. USA 84: 7473-7477 (1987).
Traversari, et al., “Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes” Immunogenetics 35: 145-152 (1992).
van der Bruggen et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma”, Science 254: 1643-1647 (Dec. 13, 1991).
Van den Eynde et al., “Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL”, Int. J. Cancer 44: 634-640 (1989).
Herin et al., “Production of Stable Cytolutic T-Cell Clones Directed Against Autologous Human Melanoma”, Int. J. Cancer 39: 390-396 (1987).
Bouchard et al., “Induction of Pigmentation in Mouse Fibroblasts By Expression of Human Tyrosinase cDNA” J. Exp. Med. 169: 2029-2042 (1989).
Boon-Falleur Thierry
Brichard Vincent
Coulie Pierre
De Plaen Etienne
Lethe Bernard
Felfe & Lynch
Ludwig Institute for Cancer Research
Schwadron Ronald B.
LandOfFree
Method of identifying individuals suffering from a cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of identifying individuals suffering from a cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of identifying individuals suffering from a cellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2531523